JP2022514759A5 - - Google Patents
Info
- Publication number
- JP2022514759A5 JP2022514759A5 JP2021535827A JP2021535827A JP2022514759A5 JP 2022514759 A5 JP2022514759 A5 JP 2022514759A5 JP 2021535827 A JP2021535827 A JP 2021535827A JP 2021535827 A JP2021535827 A JP 2021535827A JP 2022514759 A5 JP2022514759 A5 JP 2022514759A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- approximately
- vlp
- gene group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782733P | 2018-12-20 | 2018-12-20 | |
| US62/782,733 | 2018-12-20 | ||
| PCT/US2019/067961 WO2020132510A1 (en) | 2018-12-20 | 2019-12-20 | Norovirus vaccine formulations and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022514759A JP2022514759A (ja) | 2022-02-15 |
| JP2022514759A5 true JP2022514759A5 (enExample) | 2022-12-28 |
Family
ID=71101884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535827A Pending JP2022514759A (ja) | 2018-12-20 | 2019-12-20 | ノロウイルスワクチン製剤及び方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220054621A1 (enExample) |
| EP (1) | EP3897712A4 (enExample) |
| JP (1) | JP2022514759A (enExample) |
| KR (1) | KR20210114941A (enExample) |
| CN (1) | CN113453711A (enExample) |
| AR (1) | AR117462A1 (enExample) |
| AU (1) | AU2019404430A1 (enExample) |
| BR (1) | BR112021012181A2 (enExample) |
| CA (1) | CA3123860A1 (enExample) |
| CO (1) | CO2021009379A2 (enExample) |
| IL (1) | IL284233A (enExample) |
| MX (1) | MX2021007502A (enExample) |
| SG (1) | SG11202106628YA (enExample) |
| WO (1) | WO2020132510A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201601660YA (en) | 2007-09-18 | 2016-04-28 | Takeda Vaccines Inc | Method of conferring a protective immune response to norovirus |
| EP3299030B1 (en) | 2011-07-11 | 2022-06-08 | Takeda Vaccines, Inc. | Parenteral norovirus vaccine formulations |
| EP4340874A1 (en) | 2021-05-21 | 2024-03-27 | Takeda Vaccines, Inc. | Solid composition, freeze-drying method and glass vial |
| JPWO2024202045A1 (enExample) * | 2023-03-31 | 2024-10-03 | ||
| WO2025076792A1 (en) * | 2023-10-12 | 2025-04-17 | Chengdu Kanghua Biological Product Co., Ltd. | Methods of preparing norovirus vaccine with low amounts of adjuvant |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006335256B2 (en) * | 2005-11-22 | 2012-10-18 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
| SG10201601660YA (en) * | 2007-09-18 | 2016-04-28 | Takeda Vaccines Inc | Method of conferring a protective immune response to norovirus |
| KR101793161B1 (ko) * | 2008-08-08 | 2017-11-03 | 다케다 백신즈 인코포레이티드 | 강화된 교차 반응성을 가진 복합체 캡시드 아미노산 서열들을 포함하는 바이러스-유사 입자들 |
| US20110070260A1 (en) * | 2009-09-09 | 2011-03-24 | Baric Ralph S | Multivalent Immunogenic Compositions Against Noroviruses and Methods of Use |
| CA2787666A1 (en) * | 2010-01-21 | 2011-07-28 | Ligocyte Pharmaceuticals, Inc. | Targeted heterologous antigen presentation on calicivirus virus-like particles |
| EP3299030B1 (en) * | 2011-07-11 | 2022-06-08 | Takeda Vaccines, Inc. | Parenteral norovirus vaccine formulations |
-
2019
- 2019-12-19 AR ARP190103785A patent/AR117462A1/es not_active Application Discontinuation
- 2019-12-20 CA CA3123860A patent/CA3123860A1/en active Pending
- 2019-12-20 CN CN201980092246.7A patent/CN113453711A/zh active Pending
- 2019-12-20 BR BR112021012181-1A patent/BR112021012181A2/pt unknown
- 2019-12-20 MX MX2021007502A patent/MX2021007502A/es unknown
- 2019-12-20 KR KR1020217020497A patent/KR20210114941A/ko not_active Withdrawn
- 2019-12-20 SG SG11202106628YA patent/SG11202106628YA/en unknown
- 2019-12-20 WO PCT/US2019/067961 patent/WO2020132510A1/en not_active Ceased
- 2019-12-20 JP JP2021535827A patent/JP2022514759A/ja active Pending
- 2019-12-20 US US17/416,810 patent/US20220054621A1/en active Pending
- 2019-12-20 AU AU2019404430A patent/AU2019404430A1/en active Pending
- 2019-12-20 EP EP19901048.9A patent/EP3897712A4/en active Pending
-
2021
- 2021-06-20 IL IL284233A patent/IL284233A/en unknown
- 2021-07-19 CO CONC2021/0009379A patent/CO2021009379A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity | |
| Mina et al. | Live attenuated influenza vaccine enhances colonization of Streptococcus pneumoniae and Staphylococcus aureus in mice | |
| Ye et al. | Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms | |
| Marathe et al. | Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic influenza A (H5N1) virus infection in mice | |
| Maes et al. | Recent approaches in hantavirus vaccine development | |
| Osterhaus et al. | Towards universal influenza vaccines? | |
| Shinya et al. | Toll-like receptor pre-stimulation protects mice against lethal infection with highly pathogenic influenza viruses | |
| JP2009539965A5 (enExample) | ||
| JP2017515508A5 (enExample) | ||
| JP2014523878A5 (enExample) | ||
| CN103221064B (zh) | 抗流感病毒的免疫方法及其组合疫苗 | |
| US11123421B2 (en) | Cold adapted and virulence factor deleted live attenuated vaccine suitable for mucosal delivery | |
| JP2017526689A5 (enExample) | ||
| Huhti et al. | Characterization and immunogenicity of norovirus capsid-derived virus-like particles purified by anion exchange chromatography | |
| Ma et al. | Heat shock protein 70 enhances mucosal immunity against human norovirus when coexpressed from a vesicular stomatitis virus vector | |
| Feitelson et al. | Hepatitis B x (HBx) as a component of a functional cure for chronic hepatitis B | |
| CN107208071B (zh) | 用于流感病毒的减弱活疫苗 | |
| Özcengiz et al. | Two formulations of coronavirus disease‐19 recombinant subunit vaccine candidate made up of S1 fragment protein P1, S2 fragment protein P2, and nucleocapsid protein elicit strong immunogenicity in mice | |
| Zhang et al. | Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71 | |
| Allam et al. | Perspective vaccines for emerging viral diseases in farm animals | |
| JP2020537526A5 (enExample) | ||
| Zhou et al. | Recombinant adenovirus expressing type Asia1 foot-and-mouth disease virus capsid proteins induces protective immunity against homologous virus challenge in mice | |
| JP2019534242A5 (enExample) | ||
| Kim et al. | Cross-protective immune responses elicited by a Korean variant of infectious bronchitis virus | |
| Kirkpatrick et al. | Characterization of novel cross-reactive influenza B virus hemagglutinin head specific antibodies that lack hemagglutination inhibition activity |